Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by StockNews.com

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.

A number of other equities analysts have also recently commented on the company. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Finally, DA Davidson reissued a "buy" rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 0.1 %

Shares of PBH stock traded up $0.06 during trading on Friday, reaching $76.79. The company's stock had a trading volume of 217,886 shares, compared to its average volume of 285,026. Prestige Consumer Healthcare has a one year low of $60.00 and a one year high of $86.36. The business has a fifty day moving average price of $80.08 and a 200-day moving average price of $74.83. The company has a market cap of $3.79 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts' expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company's revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.07 EPS. Analysts anticipate that Prestige Consumer Healthcare will post 4.46 earnings per share for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William P'pool sold 8,987 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares of the company's stock, valued at $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 in the last quarter. Corporate insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after purchasing an additional 433 shares during the last quarter. nVerses Capital LLC lifted its position in shares of Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank boosted its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after buying an additional 181 shares in the last quarter. International Assets Investment Management LLC grew its position in Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock valued at $83,000 after acquiring an additional 1,138 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Prestige Consumer Healthcare by 49.9% in the third quarter. GAMMA Investing LLC now owns 1,163 shares of the company's stock valued at $84,000 after acquiring an additional 387 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.